Moderna (MRNA) Gross Profit (2020 - 2026)

Moderna (MRNA) has 7 years of Gross Profit data on file, last reported at -$566.0 million in Q1 2026.

• Gross Profit for Q1 2026 came in at -$566.0 million, down 3244.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $492.0 million (down 70.25% YoY), and the FY2025 annual result was $1.1 billion, down 39.28% from the prior year.
• Gross Profit declined to -$566.0 million in Q1 2026 per MRNA's latest filing, from $226.0 million in the prior quarter.
• Over five years, Gross Profit peaked at $5.0 billion in Q1 2022 and troughed at -$566.0 million in Q1 2026.
• A 5-year average of $1.2 billion and a median of $227.0 million in 2024 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2024 and 2026: Gross Profit surged 428.78% in 2024, then plunged 3244.44% in 2026.
• A 5-year view of Gross Profit shows it stood at $4.7 billion in 2022, then sank by 59.82% to $1.9 billion in 2023, then sank by 87.94% to $227.0 million in 2024, then slipped by 0.44% to $226.0 million in 2025, then sank by 350.44% to -$566.0 million in 2026.
• Business Quant data shows MRNA's Gross Profit at -$566.0 million in Q1 2026, $226.0 million in Q4 2025, and $809.0 million in Q3 2025.